Effects of a Secondary Prevention Combination Therapy with beta-Blocker and Statin on Major Adverse Cardiovascular Events in Acute Coronary Syndrome Patients

18 August 2020: Clinical Research

Ling Zhu ^12ABCDEFG , Qianwei Cui ^1BCEF , Ying Liu ^3BCEF , Zhongwei Liu ^1BCE , Yong Zhang ^1BCF , Fuqiang Liu ^1ACDEFG* , Junkui Wang ^1ACDEFG*

DOI: 10.12659/MSM.925114

Med Sci Monit 2020; 26:e925114

Table 2 Univariate and multivariate Cox analysis according to risk category of always beta-blocker and statin.

MACE*	No therapy	beta-Blocker monotherapy	Statin monotherapy	Cotherapy
MACE*	n=139	n=71	n=149	n=277
Model 1^a
HR (95% CI)	1.00	0.66 (0.36–1.21)	0.50 (0.30–0.84)	0.25 (0.15–0.43)
P value		.175	.009
Model 2^b
HR (95% CI)	1.00	0.66 (0.36–1.22)	0.50 (0.30–0.85)	0.26 (0.15–0.43)
P value		.185	.010
Model 3^c
HR (95% CI)	1.00	0.63 (0.34–1.16)	0.48 (0.28–0.80)	0.24 (0.14–0.41)
P value		.139	.006
Model 4^d
HR (95% CI)	1.00	0.59 (0.31–1.09)	0.35 (0.20–0.60)	0.16 (0.09–0.28)
P value		.092
CI – confidence interval; HR – hazard ratio; MACE – major adverse cardiac events. ^* HR and values are based on comparison with the no therapy group; ^a Model 1: Unadjusted; ^b Model 2: Multivariate adjustment was made for age, sex, smoking, body mass index; ^c Model 3: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation; ^d Model 4: Multivariate adjustment was made for age, sex, smoking, body mass index, diabetes, hypertension, old myocardial infarction, atrial fibrillation, always use of aspirin, use of clopidogrel at 1 year, always use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker, revascularization at baseline.